Research Article
OSM May Serve as a Biomarker of Poor Prognosis in Clear Cell Renal Cell Carcinoma and Promote Tumor Cell Invasion and Migration
Table 2
Differential distribution of clinicopathological parameters in high and low OSM expression groups.
| Characteristics | Low expression of OSM | High expression of OSM | value |
| | 265 | 265 | | Pathologic T stage, (%) | | | 0.019 | T1-2 | 183 (34.5%) | 157 (29.6%) | | T3-4 | 82 (15.5%) | 108 (20.4%) | | Pathologic N stage, (%) | | | 0.151 | N0 | 119 (46.7%) | 120 (47.0%) | | N1 | 5 (2.0%) | 11 (4.3%) | | Pathologic M stage, (%) | | | 0.017 | M0 | 218 (43.8%) | 202 (40.6%) | | M1 | 29 (5.8%) | 49 (9.8%) | | Pathologic stage, (%) | | | 0.011 | Stage I-II | 175 (33.2%) | 147 (27.9%) | | Stage III-IV | 88 (16.7%) | 117 (22.2%) | | Gender, (%) | | | 0.203 | Female | 100 (18.9%) | 86 (16.2%) | | Male | 165 (31.1%) | 179 (33.8%) | | Age, (%) | | | 0.082 | ≤60 | 122 (23.0%) | 142 (26.8%) | | >60 | 143 (27.0%) | 123 (23.2%) | | Histologic grade, (%) | | | 0.002 | G1-2 | 137 (26.2%) | 104 (19.9%) | | G3-4 | 121 (23.2%) | 160 (30.7%) | |
|
|